Initial pharmacokinetics and bioavailability of PSC 833, a P- glycoprotein antagonist

Journal of Clinical Pharmacology

Volumn 37, Issue 2, 1997, Pages 123-128

  Lush, Richard M ^a   Meadows, Beverly ^a   Fojo, Antonio T ^a   Kalafsky, Gaetana ^b   Smith, Harold T ^b   Bates, Susan ^a   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Sandoz Pharma Ltd   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN D; GLYCOPROTEIN P; MEMBRANE PROTEIN; VALSPODAR;

ADULT; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CREATININE CLEARANCE; DOSE RESPONSE; DRUG BIOAVAILABILITY; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MULTIDRUG RESISTANCE; PATIENT SELECTION; PROTEIN ANALYSIS; TISSUE CULTURE;

EID: 0031000057     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04770.x     Document Type: Article

References (30)

1. Biedler JL: Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic and cytogenetic studies. Cancer Res 1970;30:1174-1184.
2. Ling V, Thompson L: Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J Cell Physiol 1974;83:103-116.
3. Beck WT, Mueller TJ, Tanzer LR: Altered surface membrane glycoproteins in vinca alkaloid-resistance human leukemic lymphoblasts. Cancer Res 1979;39:2070-2076.
4. Akiyama SI, Fojo AT, Hanover JA, Pastan I, Gottesman MM: Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat Cell Mol Genet 1985;11:117-126.
5. Fairchild CR, Ivy SP, Kao-Shan CS, Whang-Peng J, Rosen N, Israel MA, et al: Isolation of amplified DNA sequences associated with pleiotropic drug resistance from human breast cancer cells. Cancer Res 1987;47:5141-5148.
6. Juliano RL, Ling V: Surface glycoprotein modulation drug permeability in Chinese hamster ovary cells mutants. Biochim Biophys Acta 1976;455:152-162.
7. Fojo AT, Akiyama SI, Gottesman MM, Pastan I: Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines. Cancer Res 1985;45:3002-3007.
8. Beck WT, Cirtain MC, Lefko JL: Energy-dependent reduced drug binding as a mechanism of vinca alkaloid resistance in human leukemic lymphoblasts. Mol Pharmacol 1983;24:485-492.
9. Gros P, Croop J, Housman D: Mammalian multidrug-resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell 1986;47:371-374.
10. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I: Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987;84:265-269.
11. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC: Cellular localization of the multidrug resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;84:7735-7738.
12. Ford JM, Hait WN: Pharmacology of drugs that alter multidrug resistance in cancer Pharmacol Rev 1990;42:155-199.
13. Keller RP, Altermatt HJ, Nooter K, Poschmann G, Laissue JA, Bollinger P, Hiestand PC: SDZ PSC 833, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia. Int J Cancer 1992;50:593-597.
14. Keller RP, Altermatt HJ, Donatsch P, Zihlmann H, Laissue JA, Hiestand PC: Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity. Int J Cancer 1992;51:433-438.
15. Zacher J, Hamilton G, Thalhammer T, Riegler M, Cosentini EP, Ellinger A, et al: Inhibition of P-glycoprotein-mediated vinblastine transport across HCT-8 intestinal carcinoma monolayers by verapamil, cyclosporine A and SDZ PSC 833 in dependence on extracellular pH. Cancer Chemother Pharmacol 1994;34:125-132.
16. Keller RP, Altermatt HJ, Nooter K, Poschmann G, Laissue JA, Bollinger P, Hiestand PC: SDZ PSC 833, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia. Int J Cancer 1992;50:593-597.
17. Watanbe T, Tsuge H, Oh-Hara T, Naito M, Tsuruo T: Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncologica 1995;34:235-241.
18. Friche E, Jensen PB, Nisen NI: Comparison of cyclosporin A and SDZ PSC 833 as multidrug-resistance modulators in a dauno-rubicin-resistant Ehrlich ascites tumor. Cancer Chemother Pharmacol 1992;30:235-237.
19. Boote DJ, Dennis IF, Twentyman PR, Osborne RJ, Laburte C, Hensel S, et al: Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 1996;14:610-618.
20. Hausdorf J, Fisher GA, Halsey J, Collins H, Lum BL, Brohpy NA, et al: A Phase I trial of etoposide with the oral cyclosporine SDZ PSC 833, a modulator of multidrug resistance (MDR). Proc Am Soc Clin Oncol 1995;14:181.
21. Lum BL, Fisher GA, Hausdorf J, Gottwald M, Collins H, Brohpy NA, et al: The effect of SDZ PSC 833, a cyclosporine D analog, on the pharmacokinetic behavior of etoposide (E) during a Phase I trial to modulate multidrug resistance. Clin Pharmacol Ther 1995;57(abstract):175.
22. Erlichman C, Moore M, Thiessen J, DeAngelis C, Goodman P, Manzo J: A Phase I trial of doxorubicin (D) and PSC833, a modulator of multidrug resistance (MDR). Proc Am Soc Clin Oncol 1994;13:134.
23. Ptachcinski RJ, Venkataramanan R, Burckart GJ, Gray JA, Van Thiel DH, Sanghvi A, et al: Cyclosporine kinetics in healthy volunteers. J Clin Pharmacol 1987;27:243.
24. Venkataramanan R, Burckart GJ, Ptachcinski RJ, Lee A, Hardesty RL, Griffith BP: Cyclosporine pharmacokinetics in heart transplant patients. Transplant Proc 1986;18:768.
25. Frey FJ, Horber FF, Frey BM: Trough levels and concentration time curves of cyclosporine in patients undergoing renal transplantation. Clin Pharmacol Ther 1988;43:55.
26. Ptachcinski RJ, Venkataramanan R, Burckart GJ: Clinical pharmacokinetics of cyclosporine. Clin Pharmacokinet 1986;11:107.
27. Ptachcinski RJ, Venkataramanan R, Rosenthal JT, Burckart GJ, Taylor RJ, Hakala TR: Cyclosporine kinetics in renal transplantation. Clin Pharmacol Ther 1985;38:296.
28. Kronbach T, Fischer V, Meyer VA: Cyclosporine metabolism in human liver: identification of a cytochrome P450III gene family as the major cyclosporine-metabolism enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988;43:630-635.
29. Ducharme MP, Warbasse LH, Edwards DJ: Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 1995;57:485-491-635.
30. Hollander AA, van Rooij J, Lentjes EG, Arbouw F, van Bree J, Schoemaker RC, et al: The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients. Clin Pharmacol Ther 1995;57:318-324.